STOCK TITAN

ADAPTIMMUNE THERAPTCS (ADAPY) Net Income by Year

ADAPY

ADAPTIMMUNE THERAPTCS reported a net loss of $70.8M in fiscal year 2024. This represents an increase of 37.8% from the prior fiscal year. Over the trailing 12 months, Q3 FY2024 through Q2 FY2025, the same line adds up to a $169.8M net loss. The table below carries 12 fiscal years, from 2013 to 2024, and the quarters ADAPTIMMUNE THERAPTCS has filed alongside them.

FY2024 annual
Net Income -$70.8M
YoY +37.8%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2025, ended Jun 30, 2025 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

ADAPY Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-K
Net Income-$169.8M-$70.8M+37.8%-$113.9M+31.2%-$165.5M-4.7%-$158.1M-21.5%-$130.1M+5.2%-$137.2M-43.6%-$95.5M-36.2%-$70.1M+2.0%-$71.6M-224.5%-$22.1M-90.1%-$11.6M-32.7%-$8.7M

TTM is the trailing twelve months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings.

ADAPY Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2510-QQ1'2510-QQ4'2410-QQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-QQ2'2310-QQ1'2310-QQ4'2210-KQ3'2210-Q
Net Income-$30.3M-143.6%-$47.6M+1.9%-$74.2M-54.9%-$17.6M+61.4%$69.5M+425.0%-$48.5M-4781.8%-$47.9M-63.8%-$45.6M-10.1%-$21.4M+52.0%$1.0M+102.1%-$29.3M+24.7%-$41.4M+2.3%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More ADAPTIMMUNE THERAPTCS financials

Frequently Asked Questions

What was ADAPTIMMUNE THERAPTCS's net income in fiscal year 2024?

ADAPTIMMUNE THERAPTCS reported a net loss of $70.8M in fiscal year 2024.

How fast is ADAPTIMMUNE THERAPTCS's net income growing?

ADAPTIMMUNE THERAPTCS (ADAPY) net income rose by 37.8% year over year, from -$113.9M to -$70.8M in fiscal year 2024.

What is ADAPTIMMUNE THERAPTCS's net income over the last twelve months?

ADAPTIMMUNE THERAPTCS (ADAPY) reported a $169.8M net loss over the trailing 12 months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings.

Across the 12 fiscal years this page covers, ADAPTIMMUNE THERAPTCS (ADAPY) net income went from -$8.7M in fiscal year 2013 to -$70.8M in fiscal year 2024.

ADAPTIMMUNE THERAPTCS (ADAPY) reported -$30.3M in net income in Q2 2025. This represents a decrease of 143.6% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what ADAPTIMMUNE THERAPTCS (ADAPY) reported on that line in every period on record.